A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administered SHR-1905 in Healthy Subjects and Subjects With Mild Asthma.
Latest Information Update: 05 May 2023
At a glance
- Drugs SHR-1905 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
- 08 Oct 2021 Status changed from not yet recruiting to recruiting.
- 01 Jun 2021 New trial record